- Home
- SCLX vs ICMB Comparison
SCLX vs ICMB Comparison
Compare SCLX & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- ICMB
- Stock Information
- Founded
- SCLX 2011
- ICMB 2012
- Country
- SCLX United States
- ICMB United States
- Employees
- SCLX N/A
- ICMB N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- ICMB Finance: Consumer Services
- Sector
- SCLX Health Care
- ICMB Finance
- Exchange
- SCLX Nasdaq
- ICMB Nasdaq
- Market Cap
- SCLX 35.7M
- ICMB 40.6M
- IPO Year
- SCLX N/A
- ICMB N/A
- Fundamental
- Price
- SCLX $26.28
- ICMB $2.92
- Analyst Decision
- SCLX Strong Buy
- ICMB
- Analyst Count
- SCLX 3
- ICMB 0
- Target Price
- SCLX $367.50
- ICMB N/A
- AVG Volume (30 Days)
- SCLX 230.4K
- ICMB 25.9K
- Earning Date
- SCLX 08-13-2025
- ICMB 11-11-2025
- Dividend Yield
- SCLX N/A
- ICMB 16.55%
- EPS Growth
- SCLX N/A
- ICMB N/A
- EPS
- SCLX N/A
- ICMB 0.93
- Revenue
- SCLX $44,236,000.00
- ICMB $20,422,069.00
- Revenue This Year
- SCLX $89.26
- ICMB N/A
- Revenue Next Year
- SCLX $203.95
- ICMB N/A
- P/E Ratio
- SCLX N/A
- ICMB $3.12
- Revenue Growth
- SCLX N/A
- ICMB N/A
- 52 Week Low
- SCLX $3.60
- ICMB $2.46
- 52 Week High
- SCLX $41.30
- ICMB $3.47
- Technical
- Relative Strength Index (RSI)
- SCLX 76.74
- ICMB 59.80
- Support Level
- SCLX $23.90
- ICMB $2.90
- Resistance Level
- SCLX $19.73
- ICMB $3.00
- Average True Range (ATR)
- SCLX 1.85
- ICMB 0.09
- MACD
- SCLX 0.50
- ICMB 0.00
- Stochastic Oscillator
- SCLX 91.79
- ICMB 51.86
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.